The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting.
Ciechanover
Aaron
A
Vascular and Tumor Biology Research Center, Faculty of Medicine, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel. c_tzachy@netvision.net.il
D000818:Animals; D015195:Drug Design; D010450:Endopeptidases / Q000378:metabolism; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D008297:Male; D008322:Mammals / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D011506:Proteins / Q000378:metabolism*; D013379:Substrate Specificity; D025801:Ubiquitin / Q000502:physiology*; D044764:Ubiquitin-Activating Enzymes / Q000378:metabolism
D011506:Proteins; D025801:Ubiquitin; D010450:Endopeptidases; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease; D044764:Ubiquitin-Activating Enzymes